Fig. 4: Response to neoadjuvant ICIs based on duration of therapy.
From: Therapeutic targeting of mismatch repair-deficient cancers
This plot presents the observed complete response (CR) rates from individual trials testing neoadjuvant immune-checkpoint inhibitors (ICIs) in patients with localized and locally advanced mismatch repair-deficient (MMRd) tumours according to the median duration of treatment. A CR includes both pathological and clinical CR (pCR and cCR, respectively). The plot is adapted from work by Rousseau et al.280. The data are reported by treatment category and cancer type, and further information is provided in Supplementary Table 3. Shown in blue is the estimated range of observed CRs across studies. CTLA4, anti-CTLA4 antibody; LAG3, anti-LAG3 antibody; PD-1, anti-PD-1 antibody; PD-L1, anti-PD-L1 antibody; COX2i, cyclooxygenase 2 inhibitor; CRC, colorectal cancer; GEJ, gastroesophageal junction; VEGFRi, vascular endothelial growth factor receptor inhibitor.
